Intelligence Feed event · Policy · 2026-10-14

    Rhythm Pharmaceuticals Launches IMCIVREE in Japan for Hypothalamic Obesity

    Question

    Rhythm Pharmaceuticals Launches IMCIVREE in Japan for Hypothalamic Obesity

    Direct answer

    Rhythm Pharmaceuticals announced the commercial rollout of IMCIVREE (setmelanotide) in Japan. The launch follows formal approval by Japan's Ministry of Health, Labour and Welfare and its inclusion on the National Health Insurance reimbursement drug price list. The designation establishes IMCIVREE as the first reimbursed pharmacotherapy for patients diagnosed with acquired hypothalamic obesity across Japanese healthcare centers.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-14
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Rhythm Pharmaceuticals Launches IMCIVREE in Japan for Hypothalamic Obesity”, revision 1, evidence through 2026-10-14. https://marketontology.com/market-events/2026-10-14/rhythm-pharmaceuticals-launches-imcivree-in-japan-for-hypothalamic-obesity-8f8379

    POLICY
    Rhythm Pharmaceuticals Launches IMCIVREE in Japan for Hypothalamic Obesity
    Rhythm Pharmaceuticals announced the commercial rollout of IMCIVREE (setmelanotide) in Japan. The launch follows formal approval by Japan's Ministry of Health, Labour and Welfare and its inclusion on the National Health Insurance reimbursement drug price list. The designation establishes IMCIVREE as the first reimbursed pharmacotherapy for patients diagnosed with acquired hypothalamic obesity across Japanese healthcare centers.
    RYTM
    Impact
    60
    OCT 14
    SIG
    90%
    RYTM
    Rhythm Pharmaceuticals Launches IMCIVREE in Japan for Hypothalamic Obesity
    Rhythm Pharmaceuticals announced the commercial rollout of IMCIVREE (setmelanotide) in Japan. The launch follows formal approval by Japan's Ministry of Health, Labour and Welfare and its inclusion on the National Health Insurance reimbursement drug price list. The designation establishes IMCIVREE as the first reimbursed pharmacotherapy for patients diagnosed with acquired hypothalamic obesity across Japanese healthcare centers.
    → National Health Insurance reimbursement listing in Japan creates commercial pricing access and revenue expansion for Rhythm Pharmaceuticals in the Asia-Pacific region.
    Impact
    Rhythm Pharmaceuticals announced the commercial rollout of IMCIVREE (setmelanotide) in Japan. The launch follows formal approval by Japan's Ministry of Health, Labour and Welfare and its inclusion on the National Health Insurance reimbursement drug price list. The designation establishes IMCIVREE as the first reimbursed pharmacotherapy for patients diagnosed with acquired hypothalamic obesity across Japanese healthcare centers.
    Affected
    RYTM
    Transmission
    National Health Insurance reimbursement listing in Japan creates commercial pricing access and revenue expansion for Rhythm Pharmaceuticals in the Asia-Pacific region.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    RYTMcommercial revenue expansion via Japan reimbursement listingUp1-3mRhythm announced commercial launch of IMCIVREE in Japan following MHLW approval and NHI drug price listing.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month